Methods of treatment using anti-ErbB antibody-maytansinoid...

Details Methods of treatment using anti-ErbB antibody-maytansinoid... Methods of treatment using anti-ErbB antibody-maytansinoid...

2006-07-17

2009-08-18

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C530S387100

Reexamination Certificate

active

07575748

ABSTRACT:
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

REFERENCES:
patent: 3896111 (1975-07-01), Kupchan et al.
patent: 4137230 (1979-01-01), Hashimoto et al.
patent: 4151042 (1979-04-01), Higashide et al.
patent: 4248870 (1981-02-01), Miyashita et al.
patent: 4256746 (1981-03-01), Miyashita et al.
patent: 4260608 (1981-04-01), Miyashita et al.
patent: 4265814 (1981-05-01), Hashimoto et al.
patent: 4294757 (1981-10-01), Asai
patent: 4307016 (1981-12-01), Asai et al.
patent: 4308268 (1981-12-01), Miyashita et al.
patent: 4308269 (1981-12-01), Miyashita et al.
patent: 4309428 (1982-01-01), Miyashita et al.
patent: 4313946 (1982-02-01), Powell et al.
patent: 4315929 (1982-02-01), Freedman et al.
patent: 4317821 (1982-03-01), Miyashita et al.
patent: 4322348 (1982-03-01), Asai et al.
patent: 4331598 (1982-05-01), Hasegawa et al.
patent: 4361650 (1982-11-01), Asai et al.
patent: 4362663 (1982-12-01), Kida et al.
patent: 4364866 (1982-12-01), Asai et al.
patent: 4371533 (1983-02-01), Akimoto et al.
patent: 4424219 (1984-01-01), Hashimoto et al.
patent: 4450254 (1984-05-01), Isley et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 4981979 (1991-01-01), Sivam
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Green et al.
patent: 5837234 (1998-11-01), Gentile et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5968517 (1999-10-01), Duncan et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6436931 (2002-08-01), Chari et al.
patent: 0 425 235 (1991-05-01), None
patent: 89/06692 (1989-07-01), None
patent: 93/21319 (1993-10-01), None
patent: 94/00136 (1994-01-01), None
patent: 94/22478 (1994-10-01), None
patent: 96/16173 (1996-05-01), None
patent: 97/00271 (1997-01-01), None
patent: 97/04801 (1997-02-01), None
patent: 98/02463 (1998-01-01), None
patent: 98/17797 (1998-04-01), None
patent: 99/31140 (1999-06-01), None
patent: 00/20579 (2000-04-01), None
patent: 00/69460 (2000-11-01), None
patent: 01/00238 (2001-01-01), None
patent: 01/00244 (2001-01-01), None
patent: 01/15730 (2001-03-01), None
Lewis, G.D. et al, Cancer Immunol. Immunother. 37: 255-263, 1993.
Xu et al. (Clinical Cancer Research vol. 3(9), pp. 1629-1634, 1997) Abstract only.
Arteaga, C. L., et al., “p185c-erbB-2Signaling Enhances Cisplatin-Induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair” Cancer Research, vol. 54, pp. 3758-3765 (1994).
Bacus, S. S. et al., “Tumor-inhibitory Monoclonals Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells”, Cancer Research, vol. 52, pp. 2580-2589 (1992).
Fendly, B. M. et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product”, Cancer Research, vol. 50, pp. 1550-1558 (1990).
Hancock, M.C. et al., A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines:, vol. 51, pp. 4575-4580 (1991).
Issell, B. F. et al., “Maytansine”, Cancer Treatment Reviews, vol. 5, pp. 199-207 (1978).
Karsprzyk, P. G. et al., “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonals Antibodies”, Cancer Research, vol. 52, pp. 2771-2776 (1992).
Kern, J. A. et al., “p185neuExpression in Human Lung Adenocarcinomas Predicts Shortened Survival”, Cancer Research, vol. 50, pp. 5184-5191 (1990).
Lewis, G.D. et al., “Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness” Cancer Research, vol. 56, pp. 1457-1465 (1996).
Maier, L. A. et al., “Requirements for the Internalization of a Murine Monoclonal Antibody Directed Against the Her-2
eu Gene Product c-erbB-2” Cancer Research, vol. 51, pp. 5361-5369 (1991).
Park, Joo-Bae et al., “Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas”, Cancer Research, vol. 49, pp. 6605-6609 (1989).
Database Chemabs Online! Chemical Abstracts Service, Columbus, Ohio, US; Skrepnik, Nebojsa et al., “Effects of anti-erbB-2 (HER-2
eu) Recombinant Oncotoxin Ar209 on Human Non-Small Cell Lung Carcinoma Grown Orthotopically in Athymic Nude Mice” retrieved from STN Database Accession No. 126:14452 XP002164007, Abstract & Clin. Cancer Research Res. (1996), 2(11), 1851-1857.
Sarup, J. C. et al., “Characterization of an Anti-p185HER2Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth”, Growth Regulation, vol. 1, pp. 72-82 (1991).
Shawyer, L. K. et al., “Ligand-like Effects Induced by Anti-c-erbB2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells”, Cancer research, vol. 54, pp. 1367-1373 (1994).
Skrepnik, N. et al., “Effects of Anti-erbB2 (HER-2
eu) Recombinant Oncotoxin AR209 on Human Non-Small Cell Lung Carcinoma Grown Orthotopically in Athymic Nude Mice”, Clinical Cancer Research, vol. 2, pp. 1851-1857 (1996).
Vitetta, E. S. et al., “Monoclonal Antibodies as Againsts: An Expanded Role for their Use in Cancer Therapy”, Cancer Research, vol. 54, pp. 5301-5309 (1994).
Weiner, D. B. et al., “Expression of the neu Gene-encoded Protein (P185neu) in Human Non-Small Cell Carcinomas of the Lung”, Cancer Research, vol. 50, pp. 421-425 (1990).
Yokota, J. et al., “Amplification of c-erbB2 Oncogene in Human Adenocarcinomas in Vivo”, The Lancet, vol. 1, pp. 765-767 (1986).
Yonemura, Y. et al., “Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer”, Cancer Research, vol. 51, pp. 1034-1038 (1991).
Aasland et al., “Expression of Oncogenes in Thyroid Tumours Coexpression of c-erbB2
eu and c-erbB”, Br. J. Cancer, vol. 57, pp. 358-363 (1988).
Bacus et al., “Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated with Loss of Cell Surface HER-2
eu Antigen”, Molecular Carcinogenesis, vol. 3, pp. 350-362 (1990).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients with HER2
eu Overexpressing Metastatic Breast Cancer”, J. Clin. Oncol., vol. 14, pp. 737-744 (1996).
Borst et al., “Oncogene Alterations in Endometrial Carcinoma”, Gynecol. Oncol., vol. 38, pp. 364-366 (1990).
Carter et al., “Humanization of anti-p185HER2Antibody for Human Cancer Therapy”, Proc. Natl. Acad. Sci. USA. vol. 89, pp. 4285-4289 (1992).
Chari et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs”, Cancer Research, vol. 52, pp. 127-131 (1992).
Chari et al., “Targeted Delivery of Chemotherapeutics: Tumor-Activated Prodrug Therapy”, Advanced Drug Delivery Reviews, vol. 31, pp. 89-104 (1998).
Cobleigh et al., “Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer that has Progressed after Cehmotherapy for Metastatic Disease”, J. Clin. Oncol., vol. 17, pp.

Affiliated with

Also associated with

Rating

Methods of treatment using anti-ErbB antibody-maytansinoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using anti-ErbB antibody-maytansinoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using anti-ErbB antibody-maytansinoid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134543